Nuventra Pharma Sciences, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Research Triangle Park NC United States (2008)

Organization Overview

First Clinical Trial
2008
NCT00738595
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ClinPharm Consulting, LLC | ClinPharm International, Leipzig, Germany | Clinpharm International Management Holding GmbH | Kinetigen, Inc | Nuventra | Nuventra, Inc. | Siro Clinpharm Germany GmbH | Siro Clinpharm Germany GmbH (until June 2013)

Active Ingredients

Drugs in Phase 4 Trials (2)

diclofenac (voltaren) (1 trial)

imiquimod (aldara) (1 trial)

Drugs in Phase 3 Trials (1)

treprostinil (remodulin) (2 trials)

Drugs in Phase 2 Trials (2)

nicotine (nicorette) (1 trial)

sembragiline (1 trial)

Drugs in Phase 1 Trials (4)

ecopipam (3 trials)

Hydroxymethylfurfural (1 trial)

mefenamic acid (ponstel) (1 trial)

valproic acid (depakene) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 1)

Familial Primary Pulmonary Hypertension (Phase 3)

Hypertension (Phase 3)

Hypertension, Pulmonary (Phase 3)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9